JP2001510462A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001510462A5 JP2001510462A5 JP1998527001A JP52700198A JP2001510462A5 JP 2001510462 A5 JP2001510462 A5 JP 2001510462A5 JP 1998527001 A JP1998527001 A JP 1998527001A JP 52700198 A JP52700198 A JP 52700198A JP 2001510462 A5 JP2001510462 A5 JP 2001510462A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76655396A | 1996-12-11 | 1996-12-11 | |
| US08/766,553 | 1996-12-11 | ||
| US08/923,346 US6552055B2 (en) | 1996-12-11 | 1997-09-04 | Methods and pharmaceutical compositions for inhibiting tumor cell growth |
| US08/923,346 | 1997-09-04 | ||
| PCT/US1997/022879 WO1998025598A2 (en) | 1996-12-11 | 1997-12-11 | Methods and pharmaceutical compositions for inhibiting tumour cell growth |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008210954A Division JP4550133B2 (ja) | 1996-12-11 | 2008-08-19 | 腫瘍細胞の成長を阻害するための方法および製薬学的組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001510462A JP2001510462A (ja) | 2001-07-31 |
| JP2001510462A5 true JP2001510462A5 (ja) | 2005-08-11 |
| JP4549443B2 JP4549443B2 (ja) | 2010-09-22 |
Family
ID=27117766
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52700198A Expired - Fee Related JP4549443B2 (ja) | 1996-12-11 | 1997-12-11 | 腫瘍細胞の成長を阻害するための方法および製薬学的組成物 |
| JP2008210954A Expired - Fee Related JP4550133B2 (ja) | 1996-12-11 | 2008-08-19 | 腫瘍細胞の成長を阻害するための方法および製薬学的組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008210954A Expired - Fee Related JP4550133B2 (ja) | 1996-12-11 | 2008-08-19 | 腫瘍細胞の成長を阻害するための方法および製薬学的組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7635708B2 (ja) |
| EP (2) | EP0948324B1 (ja) |
| JP (2) | JP4549443B2 (ja) |
| AT (2) | ATE462433T1 (ja) |
| AU (1) | AU5601898A (ja) |
| CA (1) | CA2274756C (ja) |
| DE (2) | DE69726182T2 (ja) |
| WO (1) | WO1998025598A2 (ja) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1005344A4 (en) * | 1996-12-31 | 2003-03-19 | Salk Inst For Biological Studi | TREATMENT OF LIPOSARCOMAS WITH A COMBINATION OF THIAZOLIDINEDIONS AND SELECTIVE RETINOID-X RECEPTOR AGONISTS |
| US5814647A (en) | 1997-03-04 | 1998-09-29 | Board Of Regents, The University Of Texas System | Use of troglitazone and related compounds for the treatment of the climacteric symptoms |
| FR2773075B1 (fr) | 1997-12-31 | 2000-05-05 | Cird Galderma | Utilisation d'activateurs de ppar-gamma en dermatologie |
| WO1999048529A1 (en) * | 1998-03-20 | 1999-09-30 | Warner-Lambert Company | Retinoid-glitazone combinations |
| WO2000030628A2 (en) * | 1998-11-20 | 2000-06-02 | Genentech, Inc. | Method of inhibiting angiogenesis |
| GB9908647D0 (en) * | 1999-04-15 | 1999-06-09 | Smithkline Beecham Plc | Novel compounds |
| GB9917405D0 (en) * | 1999-07-23 | 1999-09-22 | Univ Dundee | Methods of treatment and drug screening methods |
| US6723506B2 (en) | 2000-01-20 | 2004-04-20 | Brigham And Women's Hospital | Method of identifying PAX8-PPAR gamma-nucleic acid molecules |
| WO2002013864A1 (fr) * | 2000-08-16 | 2002-02-21 | Sankyo Company, Limited | Preparation medicinale de prevention et traitement du cancer |
| CA2419567A1 (en) | 2000-09-01 | 2002-03-07 | George Vande Woude | Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma |
| US7323481B2 (en) | 2001-04-06 | 2008-01-29 | Hoffmann-La Roche Inc. | Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth |
| US6756399B2 (en) | 2001-06-29 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents |
| US20040197834A1 (en) * | 2001-07-20 | 2004-10-07 | Francois Gervais | Method to increase expression of pgd2 receptors and assays for identifying modulators of prostaglandin d2 receptors |
| WO2003032988A1 (fr) * | 2001-10-17 | 2003-04-24 | Sankyo Company, Limited | Composition pharmaceutique |
| JP5249484B2 (ja) * | 2001-12-11 | 2013-07-31 | 第一三共株式会社 | 医薬組成物 |
| AU2002354460A1 (en) * | 2001-12-11 | 2003-07-09 | Sankyo Company, Limited | Medicinal composition |
| WO2003082865A1 (fr) * | 2002-04-01 | 2003-10-09 | Sankyo Company, Limited | Composition médicinale antitumorale |
| WO2004000356A1 (ja) * | 2002-06-25 | 2003-12-31 | Sankyo Company, Limited | 利尿剤及びペルオキシソーム増殖因子活性化受容体（PPAR)γ活性化剤を含有する医薬組成物 |
| JP2004083574A (ja) * | 2002-06-25 | 2004-03-18 | Sankyo Co Ltd | 利尿剤及びペルオキシソーム増殖因子活性化受容体（ＰＰＡＲ）γ活性化剤を含有する医薬組成物 |
| HU0301358D0 (en) | 2003-05-14 | 2003-07-28 | Debreceni Egyetem | Novel use of ppargamma agonists |
| WO2005003100A2 (en) * | 2003-07-03 | 2005-01-13 | Myriad Genetics, Inc. | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
| WO2006074147A2 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| TWI297606B (en) * | 2004-01-16 | 2008-06-11 | Nat Health Research Institutes | Cancer therapy |
| JP4556511B2 (ja) * | 2004-06-25 | 2010-10-06 | ソニー株式会社 | １５ｄ−ＰＧＪ２、及び、１５ｄ−ＰＧＪ２を用いた方法 |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| JP2006232754A (ja) * | 2005-02-25 | 2006-09-07 | Gi Biopolis:Kk | 消化管粘膜切除後の消化管潰瘍治癒促進用スプレー剤 |
| AU2006223000B2 (en) * | 2005-03-14 | 2011-06-30 | Center For Molecular Medicine And Immunology | Methods of treating cancer using PPAR-gamma antagonists |
| US20080194646A1 (en) | 2005-03-21 | 2008-08-14 | Sanders Martin E | Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders |
| SI1937244T1 (sl) | 2005-09-30 | 2018-12-31 | Io Therapeutics, Llc | Zdravljenje raka s specifičnimi RXR agonisti |
| CN101336113B (zh) | 2005-11-28 | 2015-07-29 | 千寿制药株式会社 | 包括ppar激动剂的药物 |
| ES2393424T3 (es) | 2007-05-21 | 2012-12-21 | Senju Pharmaceutical Co., Ltd. | Agente farmacéutico que contiene un agonista de PPAR-delta |
| WO2010070379A1 (en) * | 2008-12-17 | 2010-06-24 | Centre National De La Recherche Scientifique | Rxr-ppargamma agonist/growth factor inhibitor combination therapy for inducing apoptosis and the treatment of cancer |
| AU2012275190B2 (en) | 2011-06-29 | 2016-05-19 | The Penn State Research Foundation | Compositions, methods and kits for treating leukemia |
| MX352727B (es) | 2011-12-13 | 2017-12-06 | Dartmouth College | Tratamiento de trastorno autoinmune al usar agonistas de rxr. |
| JP5987175B2 (ja) * | 2012-07-02 | 2016-09-07 | 学校法人福岡大学 | 乳癌，胃癌及び卵巣癌等に対する制癌剤 |
| CA2890086C (en) | 2012-11-05 | 2022-05-31 | Commissariat A L'energie Atomique Et Aux Energies Alternatives (Cea) | Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist preferably a thiazolid nedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse |
| CN107073079A (zh) * | 2014-09-08 | 2017-08-18 | 达纳－法伯癌症研究所公司 | 包括给予PPAR‑γ激动剂的治疗癌症的方法 |
| WO2017075612A1 (en) * | 2015-10-31 | 2017-05-04 | Io Therapeutics, Inc. | Treatment of cancer with combinations of rxr agonists and thyroid hormones |
| PL3368080T3 (pl) | 2015-10-31 | 2023-09-11 | Io Therapeutics, Inc. | Leczenie zaburzeń układu nerwowego z zastosowaniem kombinacji agonistów rxr i hormonów tarczycy |
| US10960013B2 (en) * | 2016-03-04 | 2021-03-30 | East Carolina University | J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders |
| KR20230164204A (ko) | 2016-03-10 | 2023-12-01 | 아이오 테라퓨틱스, 인크. | Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료 |
| EP3426303B1 (en) | 2016-03-10 | 2022-06-15 | IO Therapeutics, Inc. | Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones |
| CA3076373A1 (en) | 2017-09-20 | 2019-03-28 | Io Therapeutics, Inc. | Treatment of disease with esters of selective rxr agonists |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| CA3191858A1 (en) * | 2020-09-08 | 2022-03-17 | National University Corporation Ehime University | Fluorescent dye and method for detecting tumor cells |
| US11896558B2 (en) | 2021-12-07 | 2024-02-13 | Io Therapeutics, Inc. | Use of an RXR agonist and taxanes in treating Her2+ cancers |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5071773A (en) * | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
| US5605930A (en) * | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
| ATE307795T1 (de) * | 1992-04-22 | 2005-11-15 | Ligand Pharm Inc | Verbindungen mit retinoid x rezeptorselektivität |
| US5552271A (en) * | 1992-06-16 | 1996-09-03 | La Jolla Cancer Research Foundation | RXR homodimer formation |
| US5466861A (en) * | 1992-11-25 | 1995-11-14 | Sri International | Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors |
| AU668818B2 (en) * | 1993-04-07 | 1996-05-16 | Taiho Pharmaceutical Co., Ltd. | Thiazolidine derivative and pharmaceutical composition containing the same |
| EP0724636A1 (en) | 1993-10-22 | 1996-08-07 | Ligand Pharmaceuticals, Inc. | Human peroxisome proliferator activated receptor |
| WO1995018533A1 (en) | 1994-01-04 | 1995-07-13 | The Trustees Of The University Of Pennsylvania | Methods and compounds affecting adipocyte differentiation and obesity |
| US5514821A (en) * | 1994-05-27 | 1996-05-07 | Ligand Pharmaceuticals Incorporated | Ring-labeled retinoids and intermediates, and methods for their synthesis and use |
| US5594015A (en) * | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
| JPH10502454A (ja) | 1994-07-01 | 1998-03-03 | リガンド・ファーマシューティカルズ・インコーポレーテッド | Ｎｕｃ阻害剤のスクリーニング |
| JPH10502256A (ja) | 1994-07-01 | 1998-03-03 | ザ ソールク インスチチュート フォア バイオロジカル スタディズ | 哺乳動物のペルオキシソーム増殖物質活性化受容体およびその使用 |
| JP2848964B2 (ja) | 1994-08-10 | 1999-01-20 | エフ・ホフマン−ラ ロシュ アーゲー | レチノイン酸ｘ受容体リガンド |
| US6022897A (en) * | 1995-04-25 | 2000-02-08 | The Salk Institute For Biological Studies | Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof |
| EP0824583A1 (en) * | 1995-05-04 | 1998-02-25 | City Of Hope | Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states |
| US5939442A (en) * | 1995-06-07 | 1999-08-17 | The Salk Institute For Biological Studies | Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof |
| TW474809B (en) * | 1995-07-03 | 2002-02-01 | Sankyo Co | A pharmaceutical composition for arteriosclerosis or xanthoma consisting of HMG-CoA reductase inhibitors and insulin sensitizers |
| PT859608E (pt) * | 1995-09-18 | 2004-06-30 | Ligand Pharm Inc | Tratamento de niddm com agonistas de rxr |
| AU1074897A (en) * | 1995-11-08 | 1997-05-29 | University Of South Florida | Guinea pig model for leiomyomas and atherosclerosis |
| US5814647A (en) * | 1997-03-04 | 1998-09-29 | Board Of Regents, The University Of Texas System | Use of troglitazone and related compounds for the treatment of the climacteric symptoms |
-
1997
- 1997-12-11 DE DE69726182T patent/DE69726182T2/de not_active Expired - Lifetime
- 1997-12-11 AU AU56018/98A patent/AU5601898A/en not_active Abandoned
- 1997-12-11 AT AT03078539T patent/ATE462433T1/de not_active IP Right Cessation
- 1997-12-11 EP EP97952407A patent/EP0948324B1/en not_active Expired - Lifetime
- 1997-12-11 EP EP03078539A patent/EP1410799B1/en not_active Expired - Lifetime
- 1997-12-11 JP JP52700198A patent/JP4549443B2/ja not_active Expired - Fee Related
- 1997-12-11 CA CA002274756A patent/CA2274756C/en not_active Expired - Fee Related
- 1997-12-11 AT AT97952407T patent/ATE253903T1/de active
- 1997-12-11 DE DE69739828T patent/DE69739828D1/de not_active Expired - Lifetime
- 1997-12-11 WO PCT/US1997/022879 patent/WO1998025598A2/en active IP Right Grant
-
2002
- 2002-12-19 US US10/324,744 patent/US7635708B2/en not_active Expired - Fee Related
-
2008
- 2008-08-19 JP JP2008210954A patent/JP4550133B2/ja not_active Expired - Fee Related